ClinicalTrials.gg
CompletedNCT01388361BEGIN™Updated Mar 6, 2017Results posted

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

A Phase 3 interventional study of insulin degludec and insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 124 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
33rd of 70
413 · median 384
Started
2011
with 7 others
Phase 3
49 of 70
2 open now
Registered
23rd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and North America. The aim of this trial is to compare the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec in subjects with type 2 diabetes.

Eligible subjects with an HbA1c equal to or above 7% at end of treatment in NN1250-3643 (NCT01193309) trial will be randomised to receive treatment intensification while subjects with an HbA1c below 7% at end of treatment in NN1250-3643 (NCT01193309) may continue to receive insulin degludec treatment. Subjects are to continue their pre-trial metformin treatment.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 413 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
  • The subject must have completed the end of treatment visit of NN1250-3643 with Insulin degludec once daily + metformin.
  • Ability and willingness to adhere to the protocol including self measurement of plasma glucose according to the protocol

Exclusion criteria

Exclusion Criteria:

  • Participated in NN1250-3643 and treated with insulin glargine
  • Previous treatment with glucacon like peptide (GLP-1) receptor agonists (e.g. exenatide, liraglutide)
  • Impaired liver function, defined as (ALAT) 2.5 times the at end of treatment in NN1250-3643
  • Impaired renal function defined as serum-creatinine = 125 µmol/l (= 1.4 mg/dl) for males and = 110 µmol/L (= 1.3 mg/dl) for females or according to local label for metformin [For France: below 60 ml/min, calculated by the Cockroft \& Gault formula] at end of treatment in NN1250-3643.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    IDeg (non-randomised)

    Drug: insulin degludec

  • Experimental
    IDeg + IAsp

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    IDeg + liraglutide

    Drug: insulin degludec · Drug: liraglutide

Interventions

  • Injected s.c. (under the skin) once daily. The doses will be individually adjusted

  • Injected s.c. (under the skin) once daily. The doses will be individually adjusted.

  • Injected s.c. (under the skin) once daily. The doses will be individually adjusted.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)

    Values for change in HbA1c from baseline to 26 weeks of treatment period.

    Time frame: week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Values for change in FPG in mmol/L from baseline to week 26 of randomised period.

    Time frame: week 0, week 26

  2. Change From Baseline in Body Weight

    Corresponds to the values of change in body weight in kilograms from baseline to week 26.

    Time frame: week 0, week 26

  3. Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes

    Corresponds to number of treatment emergent hypoglycaemic events from onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product. Confirmed hypoglycaemia was defined as the pool of severe hypoglycaemic episodes and minor episodes with a plasma glucose (PG) value \< 3.1 mmol/L (56 mg/dL).

    Time frame: Onset on or after the first day of exposure to investigational product for 26 weeks of treatment period and no later than 7 days after last exposure to investigational product.

08

Results

Posted Nov 26, 2015

Participant flow

The trial was conducted at 119 sites in 12 countries: Austria (4), Belgium (4), Canada (15), Czech Republic (4), Denmark (6), Finland (6), France (4), Germany (12), Norway (6), Serbia (5), Spain (7) and United States (46). These sites enrolled subjects in the randomised or non-randomised arms of the trial.

Participant flow — Overall Study
MilestoneIDegIDeg + LiraglutideIDeg + IAsp OD
Started2368889
Exposed2348786
Completed2247675
Not completed121214
Withdrew: Adverse event051
Withdrew: Protocol violation002
Withdrew: Withdrawal criteria12710
Withdrew: Unclassified001

Outcome measures

PrimaryChange From Baseline in HbA1c (%) (Glycosylated Haemoglobin)

Values for change in HbA1c from baseline to 26 weeks of treatment period.

Time frame:
week 0, week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinIDegIDeg + LiraglutideIDeg + IAsp OD
Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)0.10 ± 0.40-0.74 ± 0.73-0.39 ± 0.72
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Values for change in FPG in mmol/L from baseline to week 26 of randomised period.

Time frame:
week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegIDeg + LiraglutideIDeg + IAsp OD
Change From Baseline in Fasting Plasma Glucose (FPG)-1.23 ± 2.03-0.14 ± 2.52-0.04 ± 2.84
SecondaryChange From Baseline in Body Weight

Corresponds to the values of change in body weight in kilograms from baseline to week 26.

Time frame:
week 0, week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgIDegIDeg + LiraglutideIDeg + IAsp OD
Change From Baseline in Body Weight0.1 ± 2.7-1.0 ± 1.30.3 ± 0.9
SecondaryNumber of Severe and Minor Treatment Emergent Hypoglycaemic Episodes

Corresponds to number of treatment emergent hypoglycaemic events from onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product. Confirmed hypoglycaemia was defined as the pool of severe hypoglycaemic episodes and minor episodes with a plasma glucose (PG) value \< 3.1 mmol/L (56 mg/dL).

Time frame:
Onset on or after the first day of exposure to investigational product for 26 weeks of treatment period and no later than 7 days after last exposure to investigational product.
Reported as:
Number · events
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes
eventsIDegIDeg + LiraglutideIDeg + IAsp OD
Confirmed(severe+minor)31340330
Severe100

Adverse events

Collected over Treatment emergent adverse events were collected during 26 week treatment period + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg—11/236 (4.7%)64/236 (27.1%)
IDeg + Liraglutide—4/87 (4.6%)40/87 (46%)
IDeg + IAsp OD—5/86 (5.8%)18/86 (20.9%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventIDegIDeg + LiraglutideIDeg + IAsp OD
Vitreous detachmentEye disorders0/2360/871/86
PancreatitisGastrointestinal disorders0/2360/871/86
Humerus fractureInjury, poisoning and procedural complications0/2360/871/86
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/2360/871/86
Cerebrovascular accidentNervous system disorders0/2360/871/86
Coronary artery diseaseCardiac disorders0/2361/870/86
Gastrooesophageal reflux diseaseGastrointestinal disorders0/2361/870/86
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2361/870/86
Peripheral vascular disorderVascular disorders0/2361/870/86
Non-cardiac chest painGeneral disorders2/2360/870/86
Most frequent other events
Most frequent other events
EventIDegIDeg + LiraglutideIDeg + IAsp OD
NauseaGastrointestinal disorders3/23618/871/86
NasopharyngitisInfections and infestations43/2369/8711/86
DiarrhoeaGastrointestinal disorders8/2369/871/86
Lipase increasedInvestigations0/2366/870/86
VomitingGastrointestinal disorders4/2365/870/86
Pain in extremityMusculoskeletal and connective tissue disorders2/2365/871/86
BronchitisInfections and infestations13/2361/872/86
Upper respiratory tract infectionInfections and infestations12/2364/873/86

Baseline characteristics

The full analysis set (FAS) included all randomised patients except for 7 subjects (2 subjects with IDeg+ liraglutide; 5 subjects with IDeg+IAsp arm) fasting plasma glucose (FPG) values were missing at baseline. Non-randomised set (NAS) included all non-randomised subjects, the FPG values were missing for 10 subjects at baseline.

Age, Continuous
Age, Continuous(years)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
Mean61.9 ± 9.3NA ± NANA ± NA61.9 ± 9.3
Age, Continuous
Age, Continuous(years)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
MeanNA ± NA61.1 ± 9.560.9 ± 8.861.0 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
Female90NANANA
Male146NANANA
Sex: Female, Male
Sex: Female, Male(Participants)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
FemaleNA2536NA
MaleNA6353NA
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
Mean6.4 ± 0.4NA ± NANA ± NA6.4 ± 0.4
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
MeanNA ± NA7.7 ± 0.67.7 ± 0.87.7 ± 0.7
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
Mean6.7 ± 1.8NA ± NANA ± NA6.7 ± 1.8
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegIDeg + LiraglutideIDeg + IAsp ODTotal
MeanNA ± NA6.4 ± 2.46.1 ± 1.76.3 ± 2.1
09

Study locations

124 sites
  • Novo Nordisk Investigational Site
    Concord, California 94520-1926, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    National City, California 91950, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Palm Springs, California 92262, United States
  • Novo Nordisk Investigational Site
    Santa Monica, California 90404, United States
  • Novo Nordisk Investigational Site
    Spring Valley, California 91978, United States
  • Novo Nordisk Investigational Site
    Tarzana, California 91356-3551, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Boynton Beach, Florida 33472, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684, United States
  • Novo Nordisk Investigational Site
    West Palm Beach, Florida 33401, United States
  • Novo Nordisk Investigational Site
    Decatur, Georgia 30033, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Paducah, Kentucky 42003, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    North East, Maryland 21901, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Northport, New York 11768, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Asheboro, North Carolina 27203, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45245, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Novo Nordisk Investigational Site
    Melrose Park, Pennsylvania 19027, United States
  • Novo Nordisk Investigational Site
    Upper St. Clair, Pennsylvania 15241, United States
  • Novo Nordisk Investigational Site
    East Providence, Rhode Island 02914, United States
  • Novo Nordisk Investigational Site
    Columbia, South Carolina 29203, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Humboldt, Tennessee 38343, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Arlington, Texas 76014, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76113, United States
  • Novo Nordisk Investigational Site
    Irving, Texas 75061-2210, United States
  • Novo Nordisk Investigational Site
    Lubbock, Texas 79423, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77479, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Feldkirch, 6807, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Wolfsberg, 9400, Austria
  • Novo Nordisk Investigational Site
    Brussels, 1070, Belgium
  • Novo Nordisk Investigational Site
    Gent, 9000, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Liège, 4000, Belgium
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T5J 3N4, Canada
  • Novo Nordisk Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • Novo Nordisk Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novo Nordisk Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Novo Nordisk Investigational Site
    Mount Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • Novo Nordisk Investigational Site
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3K 0A4, Canada
  • Novo Nordisk Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • Novo Nordisk Investigational Site
    Ottawa, Ontario K1K 4L2, Canada
  • Novo Nordisk Investigational Site
    Ottawa, Ontario K1N 6N5, Canada
  • Novo Nordisk Investigational Site
    Scarborough, Ontario M1E 5E9, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Novo Nordisk Investigational Site
    St-Marc-des-Carrières, Quebec G0A 4B0, Canada
  • Novo Nordisk Investigational Site
    St. Romuald, Quebec G6W 5M6, Canada
  • Novo Nordisk Investigational Site
    Quebec, G1V 4G2, Canada
  • Novo Nordisk Investigational Site
    Brno, 65691, Czech Republic
  • Novo Nordisk Investigational Site
    Hradec Kralove, 500 05, Czech Republic
  • Novo Nordisk Investigational Site
    Plzen, 304 60, Czech Republic
  • Novo Nordisk Investigational Site
    Prague 4, 140 21, Czech Republic
  • Novo Nordisk Investigational Site
    Esbjerg, 6700, Denmark
  • Novo Nordisk Investigational Site
    Hillerød, 3400, Denmark
  • Novo Nordisk Investigational Site
    Holbæk, 4300, Denmark
  • Novo Nordisk Investigational Site
    København S, 2300, Denmark
  • Novo Nordisk Investigational Site
    Odense, 5000, Denmark
  • Novo Nordisk Investigational Site
    Silkeborg, 8600, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00260, Finland
  • Novo Nordisk Investigational Site
    Joensuu, 80100, Finland
  • Novo Nordisk Investigational Site
    Kerava, FI-04200, Finland
  • Novo Nordisk Investigational Site
    Lohja, 08100, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90100, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33210, Finland
  • Novo Nordisk Investigational Site
    Montigny-les-Metz, 57950, France
  • Novo Nordisk Investigational Site
    Nanterre, 92014, France
  • Novo Nordisk Investigational Site
    Nimes, 30006, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Berlin, 12163, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13055, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Essen, 45329, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22391, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany

Showing the first 100 of 124 sites across 12 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul;16(7):636-44. doi: 10.1111/dom.12262. Epub 2014 Feb 11. PubMed 24443830 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 3 years 4 months after primary completion. A results delay was requested in Nov 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2011
First posted
Jul 6, 2011
Start
Sep 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results delay requested
Nov 28, 2013
Results first posted
Nov 26, 2015
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01388361
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 6, 2011
Start date
Sep 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Nov 26, 2015
Last update
Mar 6, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion